Αποτελέσματα Αναζήτησης
Authors specifically recommend against treatment with menopausal estrogen therapy, treatment with menopausal estrogen plus progestogen therapy, or raloxifene, and against BMD monitoring during the five-year treatment period. For women with osteoporosis who are at least 65 years of age and have a high risk for fracture, treatment decisions ...
18 Φεβ 2020 · A Clinical Practice Guideline update has been released, which recommend romosozumab under selective criteria as another pharmacological therapy to improve osteoporosis and reduce fracture risk in postmenopausal women.
Bisphosphonates are the most widely used anti-resorptives, reducing bone turnover markers to low premenopausal concentrations and reducing fracture rates (vertebral by 50–70%, non-vertebral by 20–30%, and hip by ~40%). Bisphosphonates bind avidly to bone mineral and have an offset of effect measured in months to years.
Estrogen replacement therapy is effective for the prevention and treatment of postmenopausal osteoporosis and should be offered to all women at high risk for osteoporosis.
11 Σεπ 2024 · The treatment of osteoporosis consists of lifestyle measures and pharmacologic therapy . An overview of the approach to the prevention and treatment of osteoporosis in postmenopausal women will be presented here.
22 Αυγ 2023 · This topic will review the efficacy of estrogen therapy on the prevention and treatment of postmenopausal bone loss. The approach to osteoporosis management, the benefits and risks of estrogen therapy, and our current recommendations for estrogen use are discussed separately.
Pharmacological treatments for postmenopausal women with osteoporosis are prescribed to decrease the risk of fragility fractures. Many drugs with different mechanisms of action have been approved for the prevention and treatment of osteoporosis, are effective and available worldwide.
